



Stockholm October 27th, 2022

PRESS RELEASE

AroCell AB (publ) Interim Report January 1st to September 30th, 2022

A word from the CEO

"Another eventful and good quarter for AroCell has ended. The positive sales trend continues in our two product areas, oncology and bacteriology. It is particularly pleasing that the sales growth rate within our bacteriological segment increased during the quarter and sales within this segment have now more than doubled compared to the previous year. It feels good to see that our work is paying off. At the same time, we continue to work with our clinical programs and development projects.

Today, AroCell has a very advantageous position. We have a strong cash position, strong sales growth, and an organization that covers everything from research and development to sales, production, and distribution. Thanks to our very dedicated and competent employees, we are now seeing significant progress."

Anders Hultman, CEO

Reporting period July 1st – September 30th

- Net sales amounted to 10,401 (6,029) KSEK.
- Profit after financial items amounted to -11,069 (-17,774) KSEK
- Cash flow from operating activities for the period amounted to -1,856 (-7,810) KSEK
- Earnings per share before and after dilution amounted to -0.05 (-0.20) SEK
- Cash and cash equivalents at the end of the period amounted to 67,825 (27,825) KSEK

Reporting period January 1st – September 30th

- Net sales amounted to 24,519 (6,102) KSEK
- Profit after financial items amounted to -42,779 (-30,581) KSEK
- Cash flow from operating activities for the period amounted to -11,373 (-18,880) KSEK
- Earnings per share before and after dilution amounted to -0.20 (-0.35) SEK
- Cash and cash equivalents at the end of the period amounted to 67,825 (27,825) KSEK

Events during the reporting period July 1st – September 30th

- AroCell expands the collaboration in the Chinese market by including TPS CLIA on Fosun Diagnostics' fully automated system. Through this collaboration, AroCell's market coverage in the Chinese tumor marker market is doubled.
- AroCell continues to expand globally with new distributors and during the period signed a distribution agreement with Hospimedica covering India, for the sale of UBC[®] Rapid.



Stockholm October 27th, 2022

PRESS RELEASE

Events after the period

- The article entitled "*Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples*", by Kiran Jagarlamudi et al., was published in the journal PLOS One, where the study demonstrated the robustness and simplicity of AroCell's TK 210 ELISA assay compared to TK activity assays.
- AroCell continues to expand its business in Africa by signing a distributor agreement with MM African Technology covering Zambia and Malawi. The agreement covers the sale of TUBEX[®] TF and UBC[®] Rapid.

Interim report January 1st – September 30th, 2022 (available in Swedish only) ([Link](#))

For more information:

Anders Hultman, CEO

Telephone: +46 (0)8 799 67 50

E-mail: anders.hultman@arocell.com

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Anders Hultman, on October 27th, 2022 at 08:00.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as the company's Certified Adviser. For more information; www.arocell.com